the Russian direct investment Fund (RDIF) plans to maintain production of two drugs on the basis of “Favipiravir”. This was announced by the head of the Fund Kirill Dmitriev at the round table “experience of Russian Industrial companies to combat coronavirus”, the TV channel “Russia 24”.
In case of successful completion of clinical trials and obtaining a registration certificate will enter the market as a drug “Replevin” the company “Promomed” and drug “Coronaves” from the company “R-Pharm”.
“Favipiravir” has shown its effectiveness – ongoing clinical trials around the world. Company Glenmark (India) – have already received the check.
“Favipiravir” was studied as a potential treatment COVID-19: in China in February 2020, in March — in Japan. Before that in December 2019 was published the China study, a limitation of this study was that it was not randomized, double-blind and placebo-controlled. In March 2020 began testing in Italy.
In April-may 2020 in Russia was initiated three clinical studies phase III different variants of the drug for the treatment of COVID-19. “Aviewer” became the first in the world was a drug on the basis of “Favipiravir” against coronavirus infection. The production of “Avifauna” is a joint venture created by the Russian direct investment Fund and the company Chemrar.
In late may, the Ministry of health of Russia has approved the final phase of testing drugs, “Aviewer”, as in the first ten-stage clinical trials the drug demonstrated safety and there were no new side effects; may 29 of the same year the drug was registered for use in the hospital.
the RDIF and Chemrar ready to increase production of “Avifauna” with 700 thousand to 2 million courses a year (three times).
due To the fact that the drug RDIF and Chemrar was the first and became the reference of the new producers will be able to carry out chemical identity with “Avifauna” for the production of their products.
